Q-omics provides the consensus-scored FAM185BP profile across patient tissues and cancer cell-line models. FAM185BP expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, FAM185BP is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, FAM185BP RNA expression shows 20,494 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CHOL, THCA, and ACC as cancer lineages where FAM185BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM185BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM185BP survival associations across molecular data types. FAM185BP RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM185BP RNA expression–survival associations across cancer types. High FAM185BP expression shows unfavorable associations in LGG and ACC, but favorable associations in CHOL, HNSC, UVM and SKCM. The CHOL Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify CHOL as the clearest survival context for FAM185BP RNA expression.
This table summarizes FAM185BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM185BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM185BP shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in LIHC, COAD and KIRP. The THCA box plot shows higher FAM185BP RNA expression in normal versus tumor tissue (log2 FC = −0.915, t-test p < 0.001).
This table shows molecular features associated with FAM185BP in patient tissues and cancer cell lines. In patient samples, FAM185BP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM185BP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE.
